Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous cord blood mononuclear cells
- Development stage
- Phase 3
- Lead developer
- Mononuclear Therapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intratracheal, Intracoronary, Intrathecal
01
Overview
Autologous cord blood mononuclear cells (MNCs) are a heterogeneous population of cells derived from a patient's own umbilical cord blood, typically collected at birth and cryopreserved for future therapeutic use. This cell fraction includes hematopoietic stem cells, mesenchymal stem cells, endothelial progenitor cells, and various immune cells such as lymphocytes and monocytes. The therapy is primarily investigated for its neuroprotective and regenerative potential in pediatric neurological disorders, including cerebral palsy, neonatal ischemic stroke, and hypoxic-ischemic encephalopathy (HIE). The therapeutic effect is thought to be mediated by paracrine mechanisms, where the cells secrete anti-inflammatory cytokines, neurotrophic factors, and angiogenic signals that modulate the immune response, reduce neuroinflammation, and support endogenous tissue repair rather than through direct cell replacement.
- Other names
- autologous umbilical cord blood mononuclear cellsautologous cord blood stem cells自体脐带血单个核细胞
Beyond the preview
Go deeper on autologous cord blood mononuclear cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous cord blood mononuclear cells.